What Is Pralsetinib? RET-Positive Lung and Thyroid Cancer Explained
Pralsetinib is an oral,potent,and highly selective RET tyrosine kinase inhibitor.It targets tumors driven by RET gene rearrangements(fusions)or activating mutations,switching off the downstream signaling that fuels cancer cell growth and survival.
Genomic confirmation is mandatory.In NSCLC,RET fusion status must be validated by NGS,FISH,or RT-PCR—pathology alone is not enough.In thyroid tumors,clinicians must distinguish RET fusions from RET mutations(common in medullary thyroid cancer)because the disease context changes the treatment rationale.
For RET fusion-positive NSCLC,pralsetinib is used in adults with locally advanced or metastatic disease,both treatment-naïve and previously treated with platinum-based chemotherapy.In the ARROW study,objective response rates reached about 78%in treatment-naïve patients and 63%in those pre-treated with platinum chemotherapy.
In thyroid-related indications,it covers two pathways:
RET fusion-positive advanced or metastatic thyroid cancer that is radioactive iodine-refractory when appropriate,in adults and children aged 12 and older;
RET-mutant medullary thyroid cancer requiring systemic therapy,in adults and children aged 12 and older.
Pralsetinib is prescription-only,ideally managed by an experienced oncology team,with monitoring for hypertension,hepatotoxicity,interstitial lung disease,and bleeding risk.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)